Shorla Oncology and Eversana Announce U.S. Launch of Jylamvo

• Shorla Oncology and Eversana have launched Jylamvo (methotrexate) oral solution in the U.S.
• Jylamvo is the first and only oral methotrexate solution approved in the U.S. and provides an alternative treatment option for patients who struggle with swallowing pills.
• The drug, which was approved by the U.S. Food and Drug Administration (FDA) in November 2022, is indicated for the treatment of adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen; mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen; relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen; rheumatoid arthritis; and severe psoriasis

CAMBRIDGE, MA and CHICAGO, IL, United States – Shorla Oncology and Eversana announced the commercial launch of Jylamvo (methotrexate) oral solution in the U.S.

Jylamvo, which was approved by the U.S. Food and Drug Administration (FDA) in November 2022, is indicated for the treatment of adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen; mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen; relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen; rheumatoid arthritis; and severe psoriasis.

Shorla acquired the rights to commercialize Jylamvo in the U.S. from Therakind in October 2023. The treatment is the first and only oral methotrexate solution approved in the United States for use in adults.

Eversana, Shorla’s commercialization partner, is working to provide comprehensive launch support.

Sharon Cunningham, CEO of Shorla, said the company is “delighted to introduce Jylamvo as an alternative treatment option for patients who may have difficulty swallowing pills.”

Cunningham added, “This is our second product launch in the U.S. Market in 2023, and today's announcement is another significant advancement in our pipeline and our mission to bring new therapeutic options to patients in need.”

Jim Lang, CEO of Eversana, commented, “We have immediately activated our full commercialization engine, combined with in-depth knowledge of the complex methotrexate market, to help patients who have waited far too long for other treatment options that can help meet their needs.”

Source: Shorla Oncology